A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Biogen18 enrolled

Overview

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Small Cell Lung Cancer

Interventions

BIIB022 With Paclitaxel and CarboplatinDRUG

Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>/= 18 years old * Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer * ECOG Performance Status 0 or 1 Exclusion Criteria: * History of another primary cancer within 3 years * Any prior or concurrent investigational or standard therapy for treatment of NSCLC * Prior anti-IGF-1R therapy * Unstable diabetes

Locations (3)

Resesarch Site

Los Angeles, California, United States

Resesarch Site

San Diego, California, United States

Resesarch Site

Denver, Colorado, United States

Outcomes

Primary Outcomes

To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.